Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial.
Aim of the present study was to test, activity and toxicity of a rapidly alternating chemoradiation (paclitaxel based) in 31 patients with unresectable, locally advanced or recurrent after surgery, head and neck cancer. Three-year overall survival and progression-free survival were 61.4 and 73.7%, respectively. Main side effects remain a major problem.
Merlano
Marco
M
Department of Medical Oncology, S. Croce General Hospital, Cuneo, Italy. mcmerlano@tiscali.it
Russi
Elvio G
EG
Numico
Gianmauro
G
Colantonio
Ida
I
Garrone
Ornella
O
Pelissero
Antonio
A
Granetto
Cristina
C
Gasco
Milena
M
Di Costanzo
Gianna
G
Heouaine
Abdelhamid
A
Vigna Taglianti
Riccardo
R
Cipolat
Marco
M
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D016896:Treatment Outcome
D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil